We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+49.94%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
Cap. Flow
-$3.86M
Cap. Flow %
-0.12%
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$23.2M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$14.5M
3
CYTK icon
Cytokinetics
CYTK
+$13.8M
4
DYN icon
Dyne Therapeutics
DYN
+$13.8M
5
ZLAB icon
Zai Lab
ZLAB
+$11M

Top Sells

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$21.1M
2
CGON icon
CG Oncology
CGON
+$20M
3
IRON icon
Disc Medicine
IRON
+$12.9M
4
COGT icon
Cogent Biosciences
COGT
+$12.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
1
Mirum Pharmaceuticals
MIRM
$5.94B
$498M 14.93%
6,795,121
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.1B
$475M 14.23%
16,701,956
+94,882
+0.6% +$2.27M
VRNA
3
DELISTED
Verona Pharma
VRNA
$361M 10.82%
3,383,950
– –
BBIO icon
4
BridgeBio Pharma
BBIO
$15B
$200M 5.98%
3,845,457
+45,000
+1% +$2.19M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$2.99B
$186M 5.58%
9,874,511
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$743M
$147M 4.4%
12,466,489
– –
KRYS icon
7
Krystal Biotech
KRYS
$10.4B
$122M 3.64%
688,460
– –
MAZE
8
Maze Therapeutics
MAZE
$1.52B
$118M 3.55%
4,567,274
-1
-0% -$17
MBX
9
MBX Biosciences
MBX
$3.03B
$116M 3.49%
6,652,013
+666,666
+11% +$8.91M
IRON icon
10
Disc Medicine
IRON
$3.07B
$95.1M 2.85%
1,438,534
-216,300
-13% -$12.9M
TRVI icon
11
Trevi Therapeutics
TRVI
$2.39B
$93.9M 2.81%
10,259,409
– –
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.15B
$69.4M 2.08%
1,167,527
-230,000
-16% -$11.3M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$61.4M 1.84%
5,039,867
+152,000
+3% +$2.1M
ZLAB icon
14
Zai Lab
ZLAB
$2.93B
$55.1M 1.65%
1,627,320
+319,182
+24% +$11M
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.99B
$51.4M 1.54%
1,279,754
– –
ERAS icon
16
Erasca
ERAS
$6.31B
$49.6M 1.48%
22,729,436
– –
CYTK icon
17
Cytokinetics
CYTK
$10B
$48.9M 1.47%
890,445
+335,714
+61% +$13.8M
RVMD icon
18
Revolution Medicines
RVMD
$44.6B
$46.6M 1.4%
997,455
– –
PVLA
19
Palvella Therapeutics
PVLA
$2.16B
$45.3M 1.36%
722,400
– –
SVRA icon
20
Savara
SVRA
$1.08B
$40.9M 1.23%
11,462,301
– –
DYN icon
21
Dyne Therapeutics
DYN
$4.68B
$34.4M 1.03%
2,718,105
+1,212,121
+80% +$13.8M
ABVX
22
Abivax
ABVX
$9.89B
$32.1M 0.96%
+378,300
New +$23.2M
AURA icon
23
Aura Biosciences
AURA
$767M
$31.5M 0.94%
5,100,000
– –
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$2.52B
$29.6M 0.89%
983,715
– –
LXEO icon
25
Lexeo Therapeutics
LXEO
$399M
$29.4M 0.88%
4,424,725
– –
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2025 Portfolio in Review

As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
  • Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
  • Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
  • Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.